IP Library › Granted Patent US 7,230,032
Granted Patent B2
US 7,230,032 · App. 10/436,902 · Granted Jun 12, 2007

Calcium blockers to treat proliferative vitreoretinopathy

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,230,032
App. No.
10/436,902
Granted
Jun 12, 2007
Kind
B2
Abstract

Glutamate causes migration and proliferation of retinal pigment epithelium and/or glial cells, and glutamate antagonists can prevent, treat or reduce retinal pigment epithelium and/or glial migration and the subsequent development of proliferative vitreoretinopathy. Avoidance or management of proliferative vitreoretinopathy can be achieved by administering to the patient a compound capable of reducing glutamate-induced retinal cell migration in a concentration effective to reduce such migration.

Claims (1)

1. A method for treating proliferative vitreoretinopathy comprising administering to a patient's retina having proliferative retinopathy an effective amount of memantine.